Biofrontera AG is a biopharmaceutical company focused on the development and commercialization of dermatological products. Its primary function is to offer medical solutions for skin conditions such as actinic keratosis, a precursor to skin cancer, and basal cell carcinoma. The company stands out due to its flagship product, Ameluz®, a proprietary prescription drug used in photodynamic therapy (PDT) alongside their BF-RhodoLED® lamp, which enhances the effectiveness of this light-activated treatment process. Biofrontera AG operates globally, impacting the dermatology sector by providing innovative treatments and contributing to skin cancer management advancements. Headquartered in Germany, the company plays a significant role in the pharmaceutical market by addressing unmet medical needs in dermatology, thus improving patient care. Biofrontera's integration of drug and device strategies exemplifies its market significance and commitment to pioneering in the field of dermatological therapeutics.